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The stereoselective oxidation of hydrocarbons is an area of research where enzyme biocatalysis can 
make a substantial impact. The cyclic ketone isophorone was stereoselectively hydroxylated (≥95%) 
by wild-type CYP102A1 to form (R)-4-hydroxyisophorone, an important chiral synthon and flavour 
and fragrance compound. CYP102A1 variants were also selective for 4-hydroxyisophorone 
formation and the product formation rate increased over the wild-type enzyme by up to 285-fold, with 
the best mutants being R47L/Y51F/I401P and A74G/F87V/L188Q. The latter variant, which 
contained mutations in the distal substrate binding pocket, was marginally less selective. Combining 
perfluorodecanoic acid decoy molecules with the rate accelerating variant R47L/Y51F/I401P 
engendered further improvement with the purified enzymes. However when the decoy molecules 
were used with A74G/F87V/L188Q the amount of product generated by the enzyme was reduced. 
Addition of decoy molecules to whole-cell turnovers did not improve the productivity of these 
CYP102A1 systems. WT CYP101A1 formed significant levels of 7-hydroxyisophorone as a minor 
product alongside 4-hydroxyisophorone. However the F87W/Y96F/L244A/V247L CYP101A1 
mutant was 98% selective for (R)-4-hydroxyisophorone. A comparison of the two enzyme systems 
using whole-cell oxidation reactions showed that the best CYP101A1 variant was able to generate 
more product. We also characterised that the further oxidation metabolite 4-ketoisophorone was 
produced and then subsequently reduced to levodione by an endogenous Escherichia coli ene 
reductase. 
 





Cytochromes P450 (P450s) 1  are a family of enzymes that carry out oxidative transformations 
including hydroxylations, epoxidations, heteroatom oxidations and dealkylations as well as other 
more complex reactions [1-3]. Most P450s catalyse the oxidation of their substrate via a high-valent 
iron-oxo radical cation intermediate which inserts an oxygen atom into unactivated carbon-hydrogen 
bonds using a radical rebound mechanism [4, 5]. The key steps of the catalytic cycle are substrate 
binding, electron transfer and dioxygen binding followed by the activation of the oxygen by delivery 
of a second electron. These electrons are sourced from a nicotinamide cofactor (NADH or NADPH) 
and delivered via electron transfer partners as required [6-8]. These enzymes offer advantages over 
traditional methods of synthesis, in that the process of carbon-hydrogen bond hydroxylation occurs 
with high regio- and stereoselectivity in a single step under ambient conditions. The combination of 
all of these factors result in P450s being attractive enzymes for biocatalytic applications which could 
be used to complement traditional synthetic chemistry [9-11]. 
P450cam (CYP101A1) is a bacterial P450 that catalyses the stereospecific hydroxylation of (1R)-
camphor to 5-exo-hydroxycamphor [9, 12]. It uses a Class I electron transfer system, comprising of 
the FAD dependent, putidaredoxin reductase (PdR) and the [2Fe-2S] ferredoxin, putidaredoxin (Pdx) 
to obtain electrons from NADH [13, 14]. The development of active site mutants which catalyse the 
oxidation of alternative substrates highlighted the biocatalytic potential of CYP101A1 and this family 
of enzymes in general [9, 15-19]. For example, a number of active-site mutations introduced into 
CYP101A1 at phenylalanine 87, tyrosine 96, leucine 244 and valine 247, were found to improve its 
selectivity toward other monoterpenes, including S-limonene and (+)--pinene, enabling a route to 
                                                        
1 Abbreviations: P450, cytochrome P450; P450cam, CYP101A1 from Pseudomonas 
putida; P450BM3, CYP102A1 from Bacillus megaterium; Pdx, [2Fe-2S] ferredoxin 
from Pseudomonas putida; PdR, flavin dependant ferredoxin reductase from 
Pseudomonas putida; EMM, E. coli minimal media; PFC, perfluorocarboxcylic acid, 
IPTG, Isopropyl β-D-1-thiogalactopyranoside; TLC, Thin layer chromatography, 
NADH, reduced nicotinamide adenine dinucleotide; NADPH, reduced nicotinamide 
adenine dinucleotide phosphate; DMSO, dimethyl sulfoxide. 
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the production of compounds for the flavour and fragrance industries [20, 21]. The enzyme has also 
been altered to oxidise substrates as varied as gaseous alkanes, such as ethane, and large polycyclic 
aromatic hydrocarbons, including pyrene [15, 17, 19, 20, 22-26]. 
The cytochrome P450 CYP102A1 (P450Bm3) from Bacillus megaterium oxidises fatty acid 
substrates close to the omega terminus at high activities [27, 28]. It and other members of the 
CYP102A subfamily are unusual in that the electron transfer partner domain is fused to the heme 
domain [29-32]. CYP102A1 is soluble, easy to produce and the self-sufficient nature and high activity 
overcome two of the major hurdles to the use of P450 enzymes in synthesis. CYP102A1 has a high 
specificity for NADPH over NADH as the electron source [33], and it has been used as a template 
for the design of selective oxidation biocatalysts through rational protein engineering and directed 
evolution [9, 17, 34-37]. For example, CYP102A1 isoforms have been created which enable the 
cyclopropanation, amination and aziridination of various substrates [38-42]. CYP102A1 variants, 
which enhance the oxidation activity for unnatural substrates but do not alter the product 
regioselectivity, have been identified [43-46]. These include the R47L/Y51F (RLYF) mutant of 
CYP102A1, where the two mutations are located at the entrance of the substrate access channel, 
which enhanced the oxidation of hydrophobic unnatural substrates such as polyaromatic 
hydrocarbons [47]. Studies of other generic accelerator mutants, such as I401P and KT2 
(A191T/N239H/I259V/A276T/L353I), revealed that in the absence of substrate the rate of the first 
electron transfer step was comparable to that when a fatty acid is bound [44, 46]. Structural analysis 
of these variants has been used to rationalise this behaviour with the mutants having conformations 
which more closely resemble the fatty acid bound form of the enzyme and have longer heme-iron 
axial water interactions [44, 46]. These more catalytically ready conformations result in substrate 
binding-induced changes to the structure playing a less significant role in promoting the electron 
transfer steps. This accounted for their ability to oxidise non-natural substrates, including 
alkylbenzenes and alkanes, at elevated rates. The combination of the RLYF couple with rate 
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accelerating CYP102A1 variants has also been found to further enhance their activity [46, 48]. In 
addition CYP102A1 variants, in which phenylalanine 87 in the enzyme active site has been mutated, 
have been reported to modify the substrate binding profile and product selectivity of the enzyme [36, 
49-52]. The GVQ variant (A74G/F87V/L188Q) of CYP102A1 has been reported to be an effective 
biocatalyst for a range of organic molecules including aromatic hydrocarbons, alkanes and 
norisoprenoids [43, 53]. 
Chemically inert perfluorocarboxylic acid (PFC) decoy molecules have also been used to 
improve the activity of CYP102A1 [54]. These greatly promote the oxidation of unnatural substrates 
such as benzenes, xylenes and short chain alkanes by the wild-type (WT) enzyme [54-57]. They work 
as the shorter fluorinated fatty acid decoy molecule is used to fill part of the enzyme’s active site 
resulting in conformational changes in the enzyme. However there is enough space in the vicinity of 
the heme to allow a substrate to bind and the regioselectivity of oxidation is largely unaffected [56]. 
We have shown that it is possible to use decoy molecules, in conjugation with the rate accelerating 
mutants of CYP102A1 to substantially enhance the rates of product formation for cyclohexane and 
benzene-derived substrates and improve the productivity of regio- and stereo-selective biocatalytic 
reactions [48, 57]. 
 The selective oxidation of isophorone to 4-hydroxisophorone, which is an important flavour 
and fragrance compound as well as a synthetic intermediate for pigments and drug molecules, is a 
suitable target for biocatalytic oxidation [58-61]. Recently WT CYP102A1 was shown to be capable 
of generating 4-hydroxyisophorone on a kilogram scale [59]. During the preparation of this 
manuscript a report combining CYP101A1 variants with an alcohol dehydrogenase to generate 4-
ketoisophorone was published [62]. Here we report the stereoselective oxidation of isophorone by 
mutant forms of CYP102A1 and CYP101A1. We show that the in vitro oxidation activity with the 
CYP102A1 variants was improved using these variants and decoy molecules. Whole-cell oxidation 
of isophorone was used to compare the activity of the class I CYP101A1 system with the self-
 6 
sufficient CYP102A1 variants. Using these systems we were also able to identify the major and minor 
products arising from moonoxygenase activity and those from further processing by Escherichia coli.   
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2. Materials and Methods 
2.1 General 
General reagents and isophorone were from Sigma-Aldrich, or VWR. Buffer components, NADPH, 
and isopropyl--D-thiogalactopyranoside (IPTG) were from Astral Scientific (Australia). Production 
and purification of full-length CYP102A1 variants for in vitro use was carried out as described 
previously [43, 57]. UV/Vis spectroscopy was performed on an Agilent Cary 60 spectrophotometer. 
Gas chromatography mass spectrometry (GC-MS) analyses were carried out on a Shimadzu GC-17A 
instrument coupled to a QP5050A MS detector using a DB-5 MS fused silica column (30 m x 0.25 
mm, 0.25 µm) and helium as the carrier gas. Additional GC analysis and chiral chromatography were 
performed on a Shimadzu Tracera GC coupled to Barrier discharge Ionisation Detector (BID) detector 
using a Supelcowax column (30 m x 0.32 mm x 0.25 um) and a RT®-BDEXse chiral silica column 
(Restek; 30 m x 0.32 mm x 0.25 um), respectively. Helium was used as the carrier gas. The detailed 
GC methods used are given in the Supplementary Material. 
2.2 Activity assays 
CYP102A1 in vitro NADPH turnovers were run at 30 C in 1200 μL of 50 mM Tris, pH 7.4 at 30 °C, 
containing 0.2 μM enzyme and 120 μg bovine liver catalase. The buffer was saturated with oxygen 
gas just before use and the assays were allowed to equilibrate for 1 min prior to the addition of the 
decoy molecule (100 µM) if present, and isophorone (1 mM substrate from a 100 mM stock in 
DMSO). Finally NADPH was added, from a 20 mg mL–1 stock, to a final concentration of ~320 μM 
(equivalent to 2 AU). A period of 10 seconds was allowed to elapse after NADPH addition before the 
rate of absorbance decay at 340 nm was measured. The reactions were allowed to run until all the 
NADPH was consumed. The NADPH turnover rate was derived using ε340 = 6.22 mM−1 cm−1. Similar 
experiments in which the concentration of the added isophorone was altered (0.1 – 2 mM) were 
performed to determine the catalytic activity of the enzyme. 
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2.3 In vivo metabolite generation and product identification  
The CYP101A1 variants were screened using a plasmid system pCWSGB++ which contained the 
genes for PdR, Pdx and the relevant mutant (Table S1) [16, 17, 19, 20, 22, 23]. The DNA was 
transformed into competent DH5 Escherichia coli (E. coli) cells and a single colony was grown in 
2 x LB media and protein produced as previously described [16]. The cell pellet was harvested by 
centrifugation and resuspended in E. coli minimal media (EMM; K2HPO4, 7 g, KH2PO4, 3 g, 
Na3citrate, 0.5 g, (NH4)2SO4, 1 g, MgSO4, 0.1 g, 20% glucose, 20 mL and glycerol, 1% v/v per litre). 
Isophorone was added and the cells (30 mL in a 250 mL Erlenmeyer flask) were shaken at 200 rpm 
and 30 C. Aliquots of the turnover (1 mL, supernatant and cells) were taken and extracted with ethyl 
acetate for analysis by GC-MS.  
To isolate and identify the isophorone products, for which standards were not readily available, 
and to compare the CYP102A1 and CYP101A1 turnovers whole-cell oxidation systems utilising the 
plasmid pET28 containing the CYP102A1 gene of interest or the pCWSGB++ CYP101A1 system 
were used. The plasmids were transformed into competent BL21(DE3) cells and grown on LB plates 
containing 100 μg mL−1 ampicillin (pCW) or 30 μg mL−1 kanamycin (pET28). A single colony was 
inoculated into 500 mL 2 x LB broth in a 2 L flask and grown at 37 °C overnight or for smaller scale 
growths 50 mL in a 250 mL flask). Protein expression was induced by the addition of 60 μM IPTG 
(from a 0.4 M stock in H2O), and the temperature was reduced to 20 °C and the shaker speed to 110 
rpm. The growths were allowed to continue for another 16 h before the culture was harvested by 
centrifugation and washed with EMM. The cell pellet was resuspended in the same volume of media 
(EMM) and split into flasks as required. Isophorone (2 mM from a 100 mM stock in ethanol) was 
added to the resuspended cells (50 mL in a 250 mL flask or 200 mL in a 2 L baffled flask for large 
scale growths) the reactions were shaken at 150 rpm and 30 °C. A second aliquot of isophorone was 
added to the small scale whole-cell turnovers after 6 hours and the reactions were allowed to proceed 
for another 14 hours. For large scale turnovers two further aliquots of substrate were added after 3 
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and 6 hours. For both large and small scale reactions an aliquot of 20 x phosphate buffer (pH 7.4, 
1/40th of the total reaction volume) was added to the mixture to help maintain the pH. The large scale 
reactions were also allowed to proceed for 20 hours.  
For the comparison of the CYP101A1 and CYP102A1 variants, in vivo, the plasmid systems 
were transformed into the E. coli strain BL21(DE3) and grown in LB with the relevant antibiotics. 
The cells were harvested, resuspended in EMM and the biotransformations were performed in 
triplicate as described above (50 mL in 250 mL flask). The biomass yield was recorded as the cell 
wet weight and the concentration of P450 was determined by lysing the cells (via sonication) and 
recording the CO difference spectrum of the supernatant [63]. 
2.4 Product analysis 
After the in vitro NADPH consumption assays were completed, 990 μL of the reaction mixture was 
mixed with 10 μL of an internal standard solution (p-cresol, 20 mM stock solution in DMSO). For 
whole-cell turnovers 990 μL aliquots of the turnover (including cells) were taken for analysis (after 
addition of the same internal standard). The mixture was extracted with 400 μL of ethyl acetate and 
the organic extracts were used directly for GC-MS or GC analysis. Products were initially identified 
by matching the GC-MS mass spectra to those expected for the metabolites (see Supplementary 
Material). The amount formed was determined by calibrating against isophorone and 4-
ketoisophorone using the assumption that the hydroxyl isomeric products would give comparable 
responses e.g. 4-hydroxyisophorone and 7-hydroxyisophorone were presumed to give a similar 
detector response to isophorone. 
To determine the identity of the unknown product observed in the GC-MS analysis of the GVQ 
CYP102A1 variant (which was expected to arise from non-P450 catalysed enzyme activity) a whole-
cell turnover was performed with an E. coli containing an empty pET vector. The cells were grown 
as above and a 2 mM aliquot of 4-ketoisophorone was added. After 20 hours all the substrate had 
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been converted to a single product which was isolated and analysed by MS and NMR (Supplementary 
Material). 
Chiral normal phase HPLC analysis was carried out on a Shimadzu system equipped with a 
DGU-20A5R degasser, 2 x LC-20AR pumps, SIL-20AC HT autosampler, SPD-M20A photodiode 
array detector and a CT0-20AC column oven. Separation of the chiral products was carried out using 
a CHIRALPAK® IG column (5 μm particle size, 4.6 mm diameter x 150 mm; Daicel Chemical 
Industries Ltd.) equipped with a Chiralpak® IG guard column (5 μm particle size, 4.0 mm diameter 
x 10 mm; Daicel Chemical Industries Ltd.) operating in isocratic mode with 95% hexane and 5% 
isopropanol at 0.5 mL min1 for 38 min. The injection volume was 5 μL and the absorbance was 
monitored at 254 nm. Retention times were as follows: ketoisophorone, 14.8 min; (R)-4-
hydroxyisophorone, 26.9 min, (S)-4-hydroxyisophorone 29.4 min. 
2.5 Isolation of isophorone oxidation products 
The supernatant (200 mL) from an in vivo turnover of isophorone was extracted in ethyl acetate (3 x 
100 mL), washed with brine (100 mL) and dried with magnesium sulphate and the organic extracts 
were pooled and the solvent was removed by vacuum distillation and then under a stream of nitrogen. 
The products were purified by silica gel chromatography using a hexane/ethyl acetate stepwise 
gradient ranging from 80:20 to 50:50 hexane to ethyl acetate with 2.5 % increases every 100 mL. The 
composition of the fractions was assessed by TLC and GC-MS and those containing single products 
(95 %) were combined for characterisation. The solvent was removed under reduced pressure. 
The purified product was dissolved in CDCl3 and the organics characterised by NMR 
spectroscopy and GC-MS. NMR spectra were acquired on a Varian Unity-plus spectrometer 
operating at 500 MHz for 1H and 126 MHz for 13C. A combination of 1H, 13C, COSY, HSQC and 
HMBC experiments was used to determine the structures of the products. The specific rotation was 
determined using an Anton-Paar MCP 100 modular circular polarimeter. 
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The epoxidation of isophorone and 4-ketoisophorone was undertaken using the method of 
Fioroni and coworkers [64]. In summary, 250 μl of an aqueous solution of 2 M NaOH was added to 
1.0 mmol of substrate. The mixture was dissolved in 1.62 mL of water at 0–2 °C with stirring. After 
10 minutes 0.15 mL of 30 wt % aqueous hydrogen peroxide was added. The product was extracted 
after 6 h with ethyl acetate. Using this method approximately 30% of the isophorone was oxidised to 
isophorone oxide while the conversion for 4-ketoisophorone epoxidation was  99%. 
 The reduction of 4-ketoisophorone to generate a racemic mixture of 4-hydroxyisophorone was 
undertaken using the method of Ishihara [65]. 4-Ketoisophorone (0.4 mmol) was reduced with sodium 
borohydride (0.1 mmol) in methanol at -5 to 0 °C to afford the product which was confirmed by GC 
coelution and MS analysis with the sample isolated from the whole-cell oxidation system which had 
been characterised by NMR. This sample was used for chiral HPLC analysis. 
2.6 NMR data  
4-hydroxyisophorone: 1H NMR (500 MHz, CDCl3) δ 5.86 (s, 1H, H2), 4.03 (s, 1H, H4), 2.41 (d, J = 
16.3 Hz, 1H, H6), 2.21 (d, J = 16.3 Hz, 1H, H6), 2.06 (s, 3H, H7), 1.07 (s, 3H, H8/H9), 1.02 (s, 3H, 
H8/H9); 13C NMR (126 MHz, CDCl3): δ 202.12 (C1), 164.61 (C3), 128.64 (C2), 79.28 (C4), 51.62 
(C6), 41.17 (C5), 29.57 (C8/C9), 24.24 (C8/C9), 24.01 (C7). 
7-hydroxyisophorone: 1H NMR (500 MHz, CDCl3) δ 6.15 (s, 1H, H2), 4.22 (s, 2H, H7), 2.27 (s, 3H, 
H6), 2.14 (s, 2H, H4), 1.05 (s, 6H, H8 & H9). 13C NMR (126 MHz, CDCl3) δ 200.09 (C1), 162.22 
(C3), 122.11 (C2), 65.03 (C7), 51.56 (C6), 40.26 (C4), 33.66 (C5), 28.23 (C8 & C9). 
levodione: 1H NMR (500 MHz, CDCl3) δ 3.03 (m, 1H, H6), 2.77 (d, 1H, H5), 2.74 (d, 1H, H3), 2.52 
(d, 1H, H3), 2.35 (d, 1H, H5), 1.21 (s, 3H, CH3), 1.15 (d, 3H, CH3) 1.12 (s, 3H, CH3). 
13C NMR (126 
MHz, CDCl3): δ 216.73 (C1), 210.60 (C4) 55.38 (C3), 47.51 (C5), 46.85 (C2), 42.47 (C6), 29.16 




2.7 Substrate binding assays 
UV/Vis spectroscopy was performed on an Agilent Cary 60 spectrophotometer. For substrate binding 
the CYP102A1 enzymes were diluted to 1 - 2 µM in 50 mM Tris, pH 7.4. After addition of the 
isophorone or the PFC10 decoy molecule (as 1 µL aliquots from a 100 mM stock in DMSO or 




3.1 CYP102A1 catalysed oxidation of isophorone 
WT CYP102A1 has been shown to be capable of selective hydroxylation of isophorone but no 
enzymatic turnover data was reported [59]. We have shown that certain generic accelerator variants 
of this enzyme, which combine mutations outside of the distal active site pocket with the R47L and 
Y51F mutants at the entrance to the substrate access channel, can facilitate the oxidation of non-
physiological substrates while maintaining the selectivity. These include the R19 
(R47L/Y51F/H171L/Q307H/N319Y) and RP (R47L/Y51F/I401P) variants which have been shown 
to be effective at oxidising hydrophobic molecules such as alkylbenzenes. Decoy molecules, such as 
perfluorocarboxylic (PFC) acids, perfluorononanoic acid (PFC9) and perfluorodecanoic acid 
(PFC10), can also be combined with CYP102A1 variants to enhance the rate of oxidation of similarly 
sized substrates to isophorone [48, 55]. In these previous studies PFC10 resulted in the highest 
product formation rates due to a large increase in the turnover of the catalytic cycle whereas PFC9 
generally resulted in a higher coupling efficiency of the reducing equivalents to product formation. 
Therefore both PFC9 and PFC10 were tested with the CYP102A1 variants to see if isophorone 
oxidation could be improved. 
We determined the rates of NADPH oxidation and product formation and the coupling 
efficiency for isophorone oxidation with the purified CYP102A1 variants, in the presence and 
absence of the polyfluorinated carboxylic acids (Table 1). All the variants tested gave rise to a single 
major oxidation product using GC-MS analysis. In each turnover there were additional minor 
products, which from coelution experiments and analysis of the MS spectra were consistent with the 
further oxidation product 4-ketoisophorone and the epoxidation metabolite, isophorone oxide (Fig. 
1). The oxidation of isophorone by WT CYP102A1 was slow (PFR; 0.2 nmol(nmol-CYP)1min1; 
henceforth abbreviated to min1) and generated low levels of the hydroxylated metabolite. Addition 
of both PFC9 and PFC10 improved the overall product yield. PFC10 increased the rate of production 
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formation 29-fold as a result of increasing the NADPH oxidation rate and the coupling efficiency. 
The rate accelerating variants all increased the amount of product formation arising from isophorone 
oxidation. The product formation decreased in the order RLYFIP > R19 > KT2 > WT with the highest 
PFR being 45 min1 (Table 1).  
The oxidation of isophorone by all of these variants was also enhanced by adding the PFC9 and 
PFC10 decoy molecules. This arose due to an increase in both the NADPH oxidation activity and 
coupling efficiency resulting in more oxidation metabolites being formed in a shorter amount of time 
(Fig. 1, Table 1, Fig. S1). The product formation rate was always greater with PFC10 (Table 1). In 
line with previous studies the overall enhancement induced by the decoy molecules in rate 
accelerating variants was lower than that observed with the WT enzyme ranging from 30-fold for 
KT2 and 4-fold for RLYFIP. However the combined effect of the rate accelerating variants and decoy 
molecules produced the highest levels of isophorone oxidation. The RLYFIP variant was better than 
R19, both in the absence and presence of the decoy molecules (Table 1). The RLYFIP variant, which 
contain the RLYF couple at the entrance of the substrate access channel, was better than KT2 
predominantly due to improved coupling efficiencies (Table 1). The RLYFIP and PFC10 combination 
resulted in the highest product formation rate for isophorone, 180 min1 (Table 1). 
In order to compare the effect of the decoy molecule on the kinetic parameters we determined 
the kcat and Km for the CYP102A1 enzyme variant in the presence and absence of PFC10. It was not 
possible to determine these values accurately for the WT enzyme but for each variant the addition of 
the decoy molecule resulted in an increase in kcat and a decrease in Km (KT2: kcat; 20 min1, Km >2 
mM, KT2/PFC10: kcat; 202 ± 6 min
1, Km 380 ± 10 M; R19: kcat; 22 ± 1 min1, Km 650 ± 40 M, 
R19/PFC10: kcat; 150 ± 30 min
1, Km 440 ± 110 M and RLYFIP: kcat; 155 ± 6 min1, Km 750 ± 30 
M, RLYFIP /PFC10: kcat; 330 ± 60 min1, Km 440 ± 150 M). The kinetic parameters were also in 
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accord with lower improvements the decoy molecule induced with the R19 and RLYFIP variants 
compared to the enhancement for KT2 (Table 1, Fig. S1). 
We also tested the A74G/F87V/L188Q (GVQ) mutant with isophorone. This variant contains 
three mutations in the substrate access channel and active site of the enzyme. As such it alters the 
enzyme activity for more hydrophobic substrates and changes the selectivity of the enzyme. The 
oxidation of isophorone by this variant gave rise to the same major and minor products as the WT 
enzyme alongside an additional minor product at a later retention time (Fig. 1). The oxidation with 
the GVQ variant was more efficient, 57 min1, than RLYFIP and the other variants. This was 
predominantly due to a higher coupling efficiency (Table 1). However while the addition of the decoy 
molecules enhanced the NADPH oxidation rate with the GVQ mutant there was a significant 
reduction in the coupling efficiency and as a consequence lower levels of product formation with 
isophorone and this variant (Table 1). 
To explore the different behaviour of the GVQ variant with the decoy molecules we determined 
the spin state shift of the ferric heme after addition of PFC10 to the different CYP102A1 mutants. 
With the WT and rate accelerating variants minimal alteration in the spin state from the low-spin to 
the high-spin (HS) form, as measured by UV-Vis, was observed (15% HS). A small shift was seen 
with the rate accelerating variants following addition of isophorone after PFC10 (Fig. S2, 40% HS). 
PFC10 did induce a shift with GVQ (55% HS) indicating perturbation of the water bound to the heme-
iron. Isophorone addition to GVQ resulted in a small shift (20% HS). This increased to 50% HS 
when PFC10 and isophorone were added. Overall the data shows that the fatty acid based decoy 




3.2 Identification of the products arising from CYP102A1 oxidation of isophorone 
A single major product (>90%) was detected by GC-MS in the in vitro oxidation of isophorone by all 
CYP102A1 variants. The catalytic oxidation of isophorone by the CYP102A1 variants was 
performed, in the presence and the absence of decoy molecules, using a whole-cell system to generate 
greater quantities of this product for characterisation (Fig. S3). No material change in the levels of 
product formation was observed in vivo for either variant or when decoy molecules were added. 
Significantly more product was generated in turnovers using the variants when compared to the WT 
CYP102A1 enzyme (Fig. S4). The whole-cell turnovers with the R19 and RLYFIP variants were the 
most selective and the overall conversion of the isophorone into product was approximately 30% after 
20 hours resulting in approximately 1-1.2 mM product (as determined by the amount of product 
formed). The turnovers were combined extracted and the product was isolated, purified (6 mg after 
purification) and identified as 4-hydroxyisophorone (4-hydroxy-3,5,5-trimethyl-2-cyclohexen-1-
one), by NMR and the MS fragmentation pattern (Fig. S3 and Supplementary Material). The GVQ 
variant was less selective generating the minor metabolites observed in the in vitro turnovers in 
greater quantities (Fig. S4). The minor products were not isolated in sufficient yield or purity, from 
any of the variants, for NMR characterisation. Analysis of the MS fragmentation pattern suggested 
that the as yet unidentified later eluting product was 7-hydroxyisophorone (see Supplementary 
Material). Further oxidation to 4-ketoisophorone was also observed in the GVQ turnovers as was the 
formation of another as yet unidentified metabolite (vide infra).  
3.3 CYP101A1 catalysed oxidation of isophorone 
While there were significant improvements in the product formation of 4-hydroxyisophorone using 
the CYP102A1 variants, without and when combined with the decoy molecules, the coupling 
efficiency was moderate (Table 1). We therefore wanted to assess if other P450 enzymes could 
selectively oxidise this substrate. Previously we have shown that CYP101B1 from Novosphingobium 
aromaticivorans was able to generate three products, including 4-hydroxyisophorone, but in low yield 
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[66]. As isophorone is similar in chemical composition and size to camphor we decided to screen its 
oxidation with WT CYP101A1 and a selection of mutant forms (Table S1). We used a small library 
(fourteen including the WT enzyme) of CYP101A1 mutant enzyme encoding genes, which had 
previously been generated and cloned into a whole-cell oxidation system with the physiological 
electron transfer partners, putidaredoxin (Pdx) and putidaredoxin reductase (PdR) [16]. These 
mutants were chosen as they previously had shown good activity and selectivity with hydrocarbon 
and terpenoid based substrates such as isomers of limonene and pinene, which are of a similar size to 
isophorone [15, 19, 20, 67, 68]. 
 The screen was performed using the available whole-cell system to determine which variants 
would hydroxylate isophorone in a selective manner. WT CYP101A1 catalysed oxidation of 
isophorone generated two detectable products by GC-MS. The major product (89%) co-eluted with 
the 4-hydroxyisophorone product with the second having a later elution time, which was the same as 
that of the minor product observed in the oxidation of isophorone by the CYP102A1 GVQ variant. 
Of the CYP101A1 mutants screened with isophorone two variants were promising in that they 
generated more product and were more selective for 4-hydroxyisophorone than the WT enzyme. 
These were F87W/Y96F/V247L and F87W/Y96F/L244A/V247L which produced 4-
hydroxyisophorone at 93% and 98%, respectively (Fig. 2a). The remaining mutants tested generated 
lower levels of product and were in general less selective, though 4-hydroxyisophorone was the major 
product in all cases (Fig. 2b). 
Both products were extracted from a larger scale whole-cell oxidation turnover using the 
F87W/Y96F/V247L mutant (Fig. S5). They were purified and isolated by silica chromatography and 
the major product from both enzyme turnovers was confirmed as 4-hydroxyisophorone (35 mg; Fig. 
S3). The second less abundant product was characterised as 7-hydroxyisophorone (12 mg; 3-
hydroxymethyl-5,5-dimethyl-2-cyclohexen-1-one, Fig. S3). 
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3.4 Enantioselectivity of 4-hydoxyisophorone formation with CYP102A1 and CYP101A1. 
4-Hydroxyisophorone can be generated as two enantiomers. To analyse the enantioselectivity of the 
biocatalytic hydroxylations the turnovers were analysed by chiral chromatography. In all cases a 
single peak was observed by GC (Fig. 2b). Analysis by chiral HPLC also resulted in the observation 
of a single major peak from the enzyme catalysed reactions. The reduction of 4-ketoisophorone by 
sodium borohydride generates a racemic mixture of 4-hydroxyisophorone and this mixture was 
separated into two peaks by chiral HPLC but not GC (Fig. S6). The optical rotation of the purified 4-
hydroxyisophorone from the whole-cell turnovers of the CYP101A1 and CYP102A1 variants was 
measured in methanol. The specific rotation [𝛼]𝐷20 = +113.2 (c = 1.00, methanol) – was found to be 
in agreement with that reported in the literature for the pure (R)-enantiomer [58, 59], which is also in 
agreement with the results reported by Turner and coworkers [62]. 
3.5 Comparison of CYP102A1 and CYP101A1 systems 
CYP102A1 and it variants are often the P450 of choice for biocatalytic reactions due to their self-
sufficient nature, level and ease of production and high levels of activity. The CYP101A1 system 
requires additional electron transfer proteins but whole-cell oxidation systems of this and other class 
I systems have been generated. These also have high oxidation activity [16, 69, 70]. The CYP101A1 
variants tested here generated more product for characterisation than the CYP102A1 systems using 
the whole-cell oxidation system. A direct comparison between the two systems is not trivial due the 
disparate electron transfer systems (FMN versus iron sulfur ferredoxins, Class I versus Class III fused 
system), cofactor utilisation (NADH versus NADPH) and the different requirements of the plasmid 
systems used (pET28 versus pCWori). However we assessed if the CYP101A1 system would still 
give rise to increased levels of product when both systems were grown under similar conditions. The 
F87W/Y96F/V247L/L244A CYP101A1 system was first compared in DH5α and BL21(DE3) cells 
to see if this made a difference to the overall levels of product formation. In both types of cells almost 
all of the added substrate (4 mM) was consumed and similar levels of product (2.5 mM) were 
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generated after a 20 hour reaction suggesting the cell type is not of major significance when 
comparing the two systems (Fig. 3). 
Next the WFAL CYP101A1 variant was compared with the RLYFIP and R19 variants of 
CYP102A1. The whole-cell oxidations were carried out in BL21(DE3) cells. Both systems generated 
similar levels of cell biomass (8-10 grammes of cell wet weight per litre of culture, Table S2). The 
amount of P450 detected in the CYP102A1 variants was lower than for the WT CYP102A1 system 
(88 – 183 nM) but was substantially higher than those of the CYP101A1 system (25 – 54 nM, Table 
S2). After seven hours the level of product formed with the R19 (570 ± 100 M) was lower than 
that with RLYFIP (650 ± 100 M) which was lower again than that of the CYP101A1 system (935 
± 10 M, Fig. 4a). After leaving the samples for a further 13 hours the CYP101A1 system was able 
to convert almost all of the substrate (4 mM) to product; 2.8  4 mM of the major metabolite could 
be detected at the end of the reactions (Fig. 3). Despite the higher P450 expression levels the 
conversion in the CYP102A1 turnovers were lower and the amount of product detected was 1200 ± 
50 M and 1200 ± 100 M for the RLYFIP and R19 variants, respectively (Fig. 4a). Overall the 
whole-cell turnover of isophorone with the CYP101A1 variants seems to be better than with 
CYP102A1 (>50000 total turnovers versus 11000 for the CYP102A1 variants). The GVQ CYP102A1 
variant was also tested and the maximum levels of product formation were similar to those observed 
with the RLYFIP variant (Fig. 4b and Fig. S6). Additional oxidation products were detected during 
the whole-cell oxidations with CYP102A1 variants (Fig. S4 and Fig. S7). Two of these were assigned 
from the MS fragmentation patterns as the epoxides of isophorone and 4-ketoisophorone (Fig. 5). 
This was confirmed by coelution experiments with the products from the reactions of isophorone and 
4-ketoisophorone with hydrogen peroxide in an alkaline solution, which generates the epoxides 
(Materials and Methods). The other metabolite, which was detected during the CYP102A1 turnovers, 
had an MS fragmentation pattern consistent with that of levodione. This is formed by reduction of 
the alkene double bond of 4-ketoisophorone (Fig. 5) [62]. To verify the identity of this product we 
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ran a control reaction with 4-ketoisphorone in E. coli containing an empty pET vector. The 4-
ketoisophorone (2 mM) was completely converted in less than 20 h into the same metabolite observed 
in the enzyme turnovers. This was extracted, isolated and identified by NMR as levodione (Fig. S3, 
Supplementary Material). 




Overall the formation of 4-hydroxyisophorone by CYP102A1 was significantly increased using 
generic rate accelerator variants and the GVQ mutant. The regio- and stereoselectivity of the reaction 
was largely unaffected with all reactions giving rise to the (R)-enantiomer of 4-hydroxyisophorone 
as the major product. The most efficient in vitro turnovers contained the decoy molecule PFC10 and 
variants with the R47L/Y51F couple. However compared to smaller substrates such as cyclohexane 
and ethylbenzene the coupling efficiency of the optimal systems was moderate. The selective nature 
of the turnover suggests that the substrate is held in enzyme active site with only one CH bond close 
to the reactive iron-oxo cation radical intermediate but it must be far enough away to make the 
oxidation relatively inefficient. The larger size of isophorone may be one reason for the less efficient 
oxidation but smaller decoy molecules did not improve the levels of product formation and 
mutagenesis around the CYP102A1 active site may be required to optimise the hydroxylation further. 
One important observation from this work is that the decoy molecules did not improve 
isophorone oxidation with the A74G/F87V/L188Q CYP102A1 variant. This may arise as mutations 
at these positions in the active site and access channel of the enzyme may alter the position of fatty 
acid binding, as evidenced by the different behaviour of the spin state of this variant upon addition of 
PFC10. This would result in the decoy molecules binding closer to the heme and interfering with 
rather than enhancing the oxidation of non-natural substrates. As such the perfluorinated decoy 
molecule could now be positioned between the isophorone and the heme, displacing the iron-bound 
water and increasing the NADPH oxidation rate but resulting in a reduced C-H bond abstraction and 
coupling efficiency. The addition of the decoy molecules did not improve the whole-cell oxidation 
activity. This may be due to reduced uptake of the perfluorinated fatty acids by the cells, though 
further optimisation of the relative amounts of decoy molecule and substrate in whole-cell reactions 
may improve this [71, 72]. 
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Isophorone is of a similar size to camphor and the WT CYP101A1 enzyme was able to oxidise 
isophorone but this reaction was not as selective as WT CYP102A1. The oxidation of isophorone 
using a library of CYP101A1 mutants, derived from previous rational protein engineering studies 
(Supplementary Material), revealed that certain variants catalysed the selective formation of (R)-
hydroxyisophorone. All of these variants modified the tyrosine 96 residue which interacts with the 
camphor carbonyl group. The more hydrophobic active site of the F87W/Y96F/V247L and 
F87W/Y96F/L244A/V247L (WFAL) mutants must able to bind isophorone to enable more efficient 
and selective hydroxylation. The WFAL mutant; designed by rational mutagenesis for pinene and 
chlorinated benzene hydroxylation, was found to be the best CYP101A1 variant for isophorone 
oxidation obtained by us and also by Turner and coworkers who used a library constructed using 
saturation mutagenesis at fourteen residues in the enzyme active site [19, 20, 62]. 
A comparison between the whole-cell oxidation activities of the best CYP101A1 and 
CYP102A1 variants showed that, despite lower levels of P450 production, the class I CYP101A1 
system was superior over a longer period of time in shake flask conversions (385 mg L1). A direct 
comparison of the three component class I system versus the single component self-sufficient 
CYP102A1 system is difficult. The coupling efficiency and oxidation rates of the CYP102A1 system 
may be lower than that of the CYP101A1 variants [73]. Alternatively the concentration and rate of 
regeneration of cellular NADPH required by CYP102A1 may be different to that of NADH utilised 
by the CYP101A1 system [74-77]. The level of P450 holoprotein production of both systems in E. 
coli is known to be high but perhaps the fused CYP102A1 system is less stable under the turnover 
conditions used. The improvement in the CYP102A1 variants over the WT enzyme and the better 
whole-cell oxidation of isophorone by the CYP101A1 system should lead to refinements in the up 
sizing of this reaction. Recently researchers at DSM have scaled up the activity of WT CYP102A1 in 
a fermentor system. Using high cell densities, thirty times the amount used in our experiments, and 
the addition of additional NADPH enabled 4-hydroxyisophorone to be produced at 10 g L1 and at 
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space-time yields of 1.5 g L1 h 1 [59]. Given the low activity of the WT enzyme for this reaction 
this level of product formation is encouraging for the use of the CYP102A1 variants reported here. 
Whole-cell double oxidation of 10 mM α-isophorone to 4-ketoisophorone, using twenty times the 
amount of cells in our experiments on a 1 ml scale, was used to obtain a 65% yield of the product 
[62]. While a direct comparison of these systems is challenging due to differences in scale, biomass, 
redox partner utilisation, cofactor regeneration and the expression systems used the amount of product 
obtained from each relative to the amount of cell biomass is comparable (this work 45 mg g1 L1, 
DSM 33 mg g1 L1, double oxidation 5 mg g1 L1). Taken together these systems show promise for 




Variants of both the CYP101A1 and CYP102A1 cytochrome P450 enzymes were able to regio- and 
stereo-selectively hydroxylate isophorone to (R)-4-hydroxyisophorone. Decoy molecules were 
shown to improve the rate of product formation with the rate accelerating CYP102A1 variants but 
inhibited the performance of the A74G/F87V/L188Q variant which has mutations in the active site 
and substrate access channel. Whole-cell oxidation reactions with the optimal CYP101A1 variants 
were more productive than the best CYP102A1 mutants. The addition of decoy molecules to the 
whole-cell turnovers did not have a major effect on the levels of product formation. Further protein 
engineering of both systems could lead to more efficient systems for the oxidation of isophorone. 
Increasing the coupling efficiency of the CYP102A1 variants and improving the CYP101A1 whole-
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Table 1. NADPH oxidation rate (N), product formation rate (PFR) and coupling efficiency (C) for 
purified CYP102A1 variants with isophorone. The assays were conducted using 1mM substrate, 320 
M NADPH and 0.2 μM CYP enzyme in 50 mM Tris, pH 7.4. Coupling efficiency is the percentage 
of NADPH utilised for the formation of isophorone products. N and PFR are reported as mean  S.D. 
(n  3) and given in nmol(nmol-CYP)–1min–1. Examples of the NADH oxidation assays and the GC 
chromatogram of the product areas are provided in Fig. S2). 
 isophorone 
 N C PFR 
WT 57  2 0.3  0.1 0.2  0.1 
WT/PFC9 98  3 3.4  0.3 3.3  0.2 
WT/PFC10 318  2 1.8  0.1 5.8  0.2 
    
KT2 65  1 4.4  1 2.8  0.7 
KT2/PFC9 384  2 6.0  0.3 23  1 
KT2/PFC10 1260  10 12  1 150  5 
    
R19 148  38 8.8  0.5 13  4 
R19/PFC9 346  8 14  1 49  2 
R19/PFC10 497  34 16  1 83  6 
    
RLYFIP 425  28 11  1 45  2 
RLYFIP/PFC9 894  6 16  1 142  4 
RLYFIP/PFC10 1090  30 16  1 180  8 
    
GVQ 365  3 16  2 57  5 
GVQ/PFC9 1530  20 2.5  0.2 38  3 




List of Figures 
Figure 1 (a) GC-MS analysis of the in vitro turnover of isophorone by the CYP102A1 variants R19 
(grey) and GVQ (black). Note the chromatograms have been offset along the x-axis for clarity. 
Impurities are labelled (*), as are isophorone (RT 6.2 min), 4-hydroxyisophorone (RT 9.15 min) and 
7-hydroxyisophorone (KIP; RT 10.6 min). A small amount of the further oxidation product 4-
ketoisophorone (RT 6.6 min) was identified in both reactions. 7-Hydroxyisophorone was only 
observed in the GVQ turnover. (b) GC analysis (wax column) in the region of the 4-
hydroxyisophorone product (RT 15.3 min) for different in vitro CYP102A1 turnovers. The 
chromatograms are labelled from those which generate the lowest amount of this product to the 
highest; WT, WT+PFC10, R19, GVQ and RLYFIP (RP). See Table 1 for turnover parameters. 
Figure 2 (a) GC-MS analysis of the whole-cell turnovers of isophorone by WT CYP101A1 (black) 
and the variants WFAL (light grey) and WFL (grey). 4-Hydroxyisophorone (RT 9.0 min) and the 
minor product (7-hydroxyisophorone at RT 10.45 min) are labelled. Note the chromatograms have 
been offset along the y-axis for clarity. (b) The GC (chiral) chromatogram in the region of the 4-
hydroxyisophorone product (RT 18.7 min). The amount of product generated by the different whole-
cell CYP101A1 turnovers, from lowest to highest, was WT, F87W/Y96F/L244A, WFL and WFAL. 
Note the enantiomers of 4-hydroxyisophorone are not separated using this method. 
Figure 3 GC chromatograms (wax column) of the whole-cell turnover of the CYP101A1 variant 
WFAL after 7 (grey) and 20 hours (black). Shown are the isophorone substrate (5.8 min), internal 
standard (IS; 12.8 min) and 4-hydroxyisophorone product (15.3 min). The chromatograms have been 
slightly offset along the x- and y-axes for clarity. There was an increase in the amount of product 
(935 ± 10 M to 2.5 mM) from 7 to 20 hour samples and the majority of the added substrate (4 mM) 
was consumed at the end of the turnover. 
Figure 4 (a) GC chromatograms (wax column) of the whole-cell turnover of the CYP102A1 variant 
RLYFIP after 7 (grey) and 20 hours (black). Shown are the isophorone substrate (5.8 min), internal 
 32 
standard (IS; 12.8 min) and 4-hydroxyisophorone product (15.3 min). The chromatograms have been 
slightly offset along the x- and y-axes for clarity. Compared to the CYP101A1 WFAL whole-cell 
turnovers there were lower levels of product at both 7 (650 ± 100 M) and 20 hours (1100 ± 100 M, 
see Fig. 3). Note that there is a significant amount of unconverted substrate after 20 hours (1.5 mM). 
(b) GC-MS chromatograms of the turnover of isophorone with the CYP101A1 variant WFAL (grey) 
and the CYP102A1 variant GVQ (black). The retention times are the same as those in Figure 1. 
Additional metabolites can be seen in the GVQ turnover and include isophorone oxide (IPO; RT 5.9 
min), 4-ketoisophorone epoxide (ket ox, RT 6.9 min), 4-ketoisophorone (KIP, RP 6.2 min) and 
levodione (LD 7.1 min). See the Supplementary Material for MS analysis of the metabolites. 
Figure 5 The turnover of isophorone to (R)-4-hydroxyispophorone. The structures of the minor and 
further products which were generated in certain turnovers are also shown. 
 
